Cerebrospinal Fluid Leak During Treatment With Bevacizumab and Irinotecan After Carmustine-Impregnated Wafers Placement in Patients With Grade 2 Oligodendroglioma and Glioblastoma Multiforme: Report of Two Cases and Review of Literature

REFERENCES

• Reardon, D.A.; Wen, P.Y. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006 (Feb), 11(2), 152–164.
   PubMed Web of Science ®Google Scholar
• Adamson, C.; Kanu, O.O.; Mehta, A.I.; Di, C.; Lin, N.; Mattox, A.K.; Bigner, D.D. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 2009 Jun 26.
   PubMed Web of Science ®Google Scholar
• Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E., 2nd; Dowell, J.M.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007 (Feb 15), 13(4), 1253–1259.
   PubMed Web of Science ®Google Scholar
• Gliadel (n.d.). (Product website, homepage on the Internet). Retrieved April 29, 2009, from http://www.gliadel.com/hcp/default.aspx
   Google Scholar
• Silvani, A.; Gaviani, P.; Lamperti, E.A.; Eoli, M.; Falcone, C.; Dimeco, F.; Milanesi, I.M.; Erbetta, A.; Boiardi, A.; Fariselli, L.; Salmagi, A. Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. J Neurooncol 2009 (Feb 11), 94, 57–62.
   PubMed Web of Science ®Google Scholar
• Hart, M.G.; Grant, R.; Garside, R.; Rogers, G.; Somerville, M.; Stein, K. Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst Rev 2008 (Jul 16), 3(3), CD007294.
   PubMedGoogle Scholar
• Jain, R.K.; di Tomaso, E.; Duda, D.G.; Loeffler, J.S.; Sorensen, A.G.; Batchelor, T.T. Angiogenesis in brain tumours. Nat Rev Neurosci 2007 (Aug), 8(8), 610–622.
   PubMed Web of Science ®Google Scholar
• Wong, E.T.; Brem, S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol 2007 (Oct 20), 25(30), 4705–4706.
   PubMed Web of Science ®Google Scholar
• Winkler, F.; Kozin, S.V.; Tong, R.T.; Chae, S.S.; Booth, M.F.; Garkavtsev, I.; Xu, L.; Hicklin, D.J.; Fukumura, D.; di Tomaso, E.; Munn, L.L.; Jain, R.K.; et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004 (Dec), 6(6), 553–563.
   PubMed Web of Science ®Google Scholar
• Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E., 2nd; Dowell, J.M.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S; et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007 (Feb 15), 13(4), 1253–1259.
   PubMed Web of Science ®Google Scholar
• Kreisl, T.N.; Kim, L.; Moore, K.; Duic, P.; Royce, C.; Stroud, I.; Garren, N.; Mackey, M.; Butman, J.A.; Camphausen, K.; Park, J.; Albert, P.S.; Fine, H.A. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009 (Feb 10), 27(5), 740–745.
   PubMed Web of Science ®Google Scholar
• Gonzalez, J.; Kumar, A.J.; Conrad, C.A.; Levin, V.A. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007 (Feb 1), 67(2), 323–326.
   PubMed Web of Science ®Google Scholar
• Torcuator, R.; Zuniga, R.; Mohan, Y.S.; Rock, J.; Doyle, T.; Anderson, J.; Gutierrez, J.; Ryu, S.; Jain, R.; Rosenblum, M.; Mikkelsen, T. Initial experience with bevacizumab treatment for biopsy-confirmed cerebral radiation necrosis. J Neurooncol 2009 (Feb 3), 94, 63–68.
   PubMed Web of Science ®Google Scholar
• Chamberlain, M.C. Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol 2008 (Feb 20), 26(6), 1012–1013 (author reply 1013).
   PubMed Web of Science ®Google Scholar
• Dyke, J.P.; Sanelli, P.C.; Voss, H.U.; Serventi, J.V.; Stieg, P.E.; Schwartz, T.H.; Ballon, D.; Shungu, D.C.; Pannullo, S.C. Monitoring the effects of BCNU chemotherapy wafers (gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 tesla. J Neurooncol 2007 (Mar), 82(1), 103–110.
   PubMed Web of Science ®Google Scholar
• Nghiemphu, P.L.; Green, R.M.; Pope, W.B.; Lai, A.; Cloughesy, T.F. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008 (Jun), 10(3), 355–360.
   PubMed Web of Science ®Google Scholar
• BCNU-impregnated wafers (gliadel) plus irinotecan (camptosar) in combination treatment for patients with recurrent glioblastoma multiforme (n.d.). (Homepage on the Internet). Retrieved April 20, 2009, from http://abstracts.neurosurgeon.org/view.php?id=19824
   Google Scholar
• Westphal, M.; Hilt, D.C.; Bortey, E.; Delavault, P.; Olivares, R.; Warnke, P.C.; Whittle, I.R.; Jaaskelainen, J.; Ram, Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003 (April), 5(2), 79–88.
   PubMed Web of Science ®Google Scholar
• Brem, H.; Piantadosi, S.; Burger, P.C.; Walker, M.; Selker, R.; Vick, N.A.; Black, K.; Sisti, M.; Brem, S.; Mohr, G. Placebo-controlled trial of safety and efficacy of intraoperative-controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 1995 (Apr 22), 345(8956), 1008–1012.
   PubMed Web of Science ®Google Scholar
• Attenello, F.J.; Mukherjee, D.; Datoo, G.; McGirt, M.J.; Bohan, E.; Weingart, J.D.; Olivi, A.; Quinones-Hinojosa, A.; Brem, H. Use of gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008 (Oct), 15(10), 2887–2893.
   PubMed Web of Science ®Google Scholar
• Quinn, J.A.; Jiang, S.X.; Carter, J.; Reardon, D.A.; Desjardins, A.; Vredenburgh, J.J.; Rich, J.N.; Gururangan, S.; Friedman, A.H.; Bigner, D.D.; Sampson, J.H.; McLendon, R.E.; Herndon, J.E., 2nd; Threatt, S.; Friedman, H.S. Phase II trial of gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 2009 (Feb 1), 15(3), 1064–1068.
   PubMed Web of Science ®Google Scholar
• Smith, K.A.; Ashby, L.S.; Gonzalez, F.; Brachman, D.G.; Thomas, T.; Coons, S.W.; Battaglia, M.; Scheck, A. Prospective trial of gross-total resection with gliadel wafers followed by early postoperative gamma knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J Neurosurg 2008 (Dec), 109 (Suppl), 106–117.
   PubMedGoogle Scholar
• Gallego, J.M.; Barcia, J.A.; Barcia-Marino, C. Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir 2007 (Mar), 149(3), 261, 265 (discussion 265).
   PubMed Web of Science ®Google Scholar
• Brown, E.M. Antimicrobial prophylaxis in neurosurgery. J Antimicrob Chemother 1993 (Feb), 31 (Suppl B), 49–63.
   PubMed Web of Science ®Google Scholar
• Weber, E.L.; Goebel, E.A. Cerebral edema associated with gliadel wafers: two case studies. Neuro Oncol 2005 (Jan), 7(1), 84– 89.
   PubMed Web of Science ®Google Scholar
• Lawson, H.C.; Sampath, P.; Bohan, E.; Park, M.C.; Hussain, N.; Olivi, A.; Weingart, J.; Kleinberg, L.; Brem, H. Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol 2007 (May), 83(1), 61–70.
   PubMed Web of Science ®Google Scholar
• Congress of Neurological Surgeons 2008 annual meeting (n.d.). (Homepage on the Internet). Retrieved April 20, 2009, from http://abstracts.neurosurgeon.org/view.php?id=3140
   Google Scholar
• Subach, B.R.; Witham, T.F.; Kondziolka, D.; Lunsford, L.D.; Bozik, M.; Schiff, D. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 1999 (Jul), 45(1), 17, 22–23 (discussion 22–23).
   PubMed Web of Science ®Google Scholar
• Perry, J.; Chambers, A.; Spithoff, K.; Laperriere, N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 2007 (Oct), 14(5), 189–194.
   PubMedGoogle Scholar
• Barnholtz-Sloan, J.S.; Williams, V.L.; Maldonado, J.L.; Shahani, D.; Stockwell, H.G.; Chamberlain, M.; Sloan, A.E. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 2008 (Apr), 108(4), 642–648.
   PubMed Web of Science ®Google Scholar
• Scappaticci, F.A.; Fehrenbacher, L.; Cartwright, T.; Hainsworth, J.D.; Heim, W.; Berlin, J.; Kabbinavar, F.; Novotny, W.; Sarkar, S.; Hurwitz, H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005 (Sep 1), 91(3), 173–180.
   PubMed Web of Science ®Google Scholar
• Avastin and metastatic colorectal cancer treatment information—avastin. (n.d.). (Homepage on the Internet). Retrieved April 29, 2009, from http://www.avastin.com/avastin/patient/crc/
   Google Scholar
• Genentech medicines: Avastin. (n.d.). (Homepage on the Internet). Retrieved May 7, 2009, from http://www.gene.com/gene/products/information/oncology/avastin/
   Google Scholar
• Goodgame, B.; Veeramachaneni, N.; Patterson, A.; Govindan, R. Tracheo-esophageal fistula with bevacizumab after mediastinal radiation. J Thorac Oncol 2008 (Sep), 3(9), 1080–1081.
   PubMed Web of Science ®Google Scholar
• Chereau, E.; Stefanescu, D.; Selle, F.; Rouzier, R.; Darai, E. Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report. Am J Obstet Gynecol 2009 (Jan), 200(1), e15–e16.
   PubMed Web of Science ®Google Scholar
• Garcia, A.A.; Hirte, H.; Fleming, G.; Yang, D.; Tsao-Wei, D.D.; Roman, L.; Groshen, S.; Swenson, S.; Markland, F.; Gandara, D.; Scudder, S.; Morgan, R.; Chen, H.; Lenz, H.J.; Oza, A.M. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008 (Jan 1), 26(1), 76–82.
   PubMed Web of Science ®Google Scholar
• A study of gliadel followed by avastin + irinotecan for glioblastoma multiforme (GBM): full text view—ClinicalTrials.gov. (n.d.). (Homepage on the Internet). Retrieved February 12, 2009, from http://clinicaltrials.gov/ct2/show/NCT00735436?term=Gliadel&rank=2
   Google Scholar